Studying copy number variations using a nanofluidic platform

Copy number variations (CNVs) in the human genome are conventionally detected using high-throughput scanning technologies, such as comparative genomic hybridization and high-density single nucleotide polymorphism (SNP) microarrays, or relatively low-throughput techniques, such as quantitative polymerase chain reaction (PCR). All these approaches are limited in resolution and can at best distinguish a twofold (or 50%) difference in copy number. We have developed a new technology to study copy numbers using a platform known as the digital array, a nanofluidic biochip capable of accurately quantitating genes of interest in DNA samples. We have evaluated the digital array's performance using a model system, to show that this technology is exquisitely sensitive, capable of differentiating as little as a 15% difference in gene copy number (or between 6 and 7 copies of a target gene). We have also analyzed commercial DNA samples for their CYP2D6 copy numbers and confirmed that our results were consistent with those obtained independently using conventional techniques. In a screening experiment with breast cancer and normal DNA samples, the ERBB2 gene was found to be amplified in about 35% of breast cancer samples. The use of the digital array enables accurate measurement of gene copy numbers and is of significant value in CNV studies.

[1]  Carolyn J. Brown,et al.  A comprehensive analysis of common copy-number variations in the human genome. , 2007, American journal of human genetics.

[2]  A. Molven,et al.  Ultrarapid metabolizers of debrisoquine: Characterization and PCR‐based detection of alleles with duplication of the CYP2D6 gene , 1996, FEBS letters.

[3]  E. Birney,et al.  Challenges and standards in integrating surveys of structural variation , 2007, Nature Genetics.

[4]  Ramesh Ramakrishnan,et al.  High Throughput Gene Expression Measurement with Real Time PCR in a Microfluidic Dynamic Array , 2008, PloS one.

[5]  A. Bast,et al.  Review article: the prevalence and clinical relevance of cytochrome P450 polymorphisms , 2007, Alimentary pharmacology & therapeutics.

[6]  David Cameron,et al.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial , 2007, The Lancet.

[7]  Laurent Bodin,et al.  Determination of Cytochrome P450 2D6 (CYP2D6) Gene Copy Number by Real-Time Quantitative PCR , 2005, Journal of biomedicine & biotechnology.

[8]  Urs A. Meyer,et al.  Overview of enzymes of drug metabolism , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[9]  T. Lynch,et al.  The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. , 2007, American family physician.

[10]  J. Silver,et al.  Nanoliter scale PCR with TaqMan detection. , 1997, Nucleic acids research.

[11]  S. Swain,et al.  Ongoing adjuvant trials with trastuzumab in breast cancer. , 2003, Seminars in oncology.

[12]  R. Berecz,et al.  Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs. , 2006, Current drug targets.

[13]  C. Huxley,et al.  Recombining overlapping BACs into a single larger BAC , 2004, BMC biotechnology.

[14]  Ramesh Ramakrishnan,et al.  Mathematical Analysis of Copy Number Variation in a DNA Sample Using Digital PCR on a Nanofluidic Device , 2008, PloS one.

[15]  J. Schellens,et al.  Pharmacogenetic Screening of the Gene Deletion and Duplications of CYP2D6 , 2007, Drug metabolism reviews.

[16]  J. Lupski,et al.  Genomic rearrangements and sporadic disease , 2007, Nature Genetics.

[17]  D. Conrad,et al.  Global variation in copy number in the human genome , 2006, Nature.

[18]  R. Bohle,et al.  HER-2/neu gene copy number quantified by real-time PCR: comparison of gene amplification, heterozygosity, and immunohistochemical status in breast cancer tissue. , 2003, Clinical chemistry.

[19]  M. Eichelbaum,et al.  Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. , 1991, American journal of human genetics.

[20]  I. Baldwin,et al.  Two-fold differences are the detection limit for determining transgene copy numbers in plants by real-time PCR , 2004, BMC biotechnology.

[21]  R. Skoda,et al.  The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. , 1989, American journal of human genetics.

[22]  A. Brookes.  The essence of SNPs. , 1999, Gene.

[23]  M. Baer,et al.  Structure and transcription of a human gene for H1 RNA, the RNA component of human RNase P , 1990, Nucleic Acids Res..

[24]  D. Slamon,et al.  Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. , 1996, Oncogene.

[25]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[26]  S. Bustin,et al.  Intracellular expression profiles measured by real-time PCR tomography in the Xenopus laevis oocyte , 2007, Nucleic acids research.

[27]  W. Holzgreve,et al.  Novel real-time quantitative PCR test for trisomy 21. , 2002, Clinical chemistry.

[28]  R. Tubbs,et al.  HER2 testing: a review of detection methodologies and their clinical performance , 2007, Expert review of molecular diagnostics.

[29]  J Kirchheiner,et al.  The clinical role of genetic polymorphisms in drug-metabolizing enzymes , 2008, The Pharmacogenomics Journal.

[30]  Kenny Q. Ye,et al.  Large-Scale Copy Number Polymorphism in the Human Genome , 2004, Science.

[31]  M. Bui,et al.  Prognostic and predictive value of HER2/neu oncogene in breast cancer , 2002, Microscopy research and technique.

[32]  E. Eichler,et al.  Recent duplication, domain accretion and the dynamic mutation of the human genome. , 2001, Trends in genetics : TIG.

[33]  N. Carter,et al.  Autosomal-dominant microtia linked to five tandem copies of a copy-number-variable region at chromosome 4p16. , 2008, American Journal of Human Genetics.

[34]  N. Carter.  Methods and strategies for analyzing copy number variation using DNA microarrays , 2007, Nature Genetics.

[35]  K. Kinzler,et al.  Digital PCR. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  E. Eichler,et al.  Segmental duplications and copy-number variation in the human genome. , 2005, American journal of human genetics.

[37]  Yong-shu He,et al.  [Structural variation in the human genome]. , 2009, Yi chuan = Hereditas.

[38]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[39]  M. Eichelbaum,et al.  CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real‐rime PCR , 2003, Human mutation.

[40]  Tak Y. Leung,et al.  Digital PCR for the molecular detection of fetal chromosomal aneuploidy , 2007, Proceedings of the National Academy of Sciences.

[41]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[42]  U. Meyer.  Pharmacogenetics and adverse drug reactions , 2000, The Lancet.

[43]  J. Weide,et al.  Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication. , 1998, Clinical chemistry.

[44]  A. Daly,et al.  Individualized drug therapy. , 2007, Current opinion in drug discovery & development.

[45]  L. Feuk,et al.  Detection of large-scale variation in the human genome , 2004, Nature Genetics.

[46]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[47]  P. Lamy,et al.  Reliability and discriminant validity of HER2 gene quantification and chromosome 17 aneusomy analysis by real-time PCR in primary breast cancer. , 2006, The International journal of biological markers.

[48]  H. Ropers.  New perspectives for the elucidation of genetic disorders. , 2007, American journal of human genetics.

[49]  R. Danesi,et al.  CYP2D6 polymorphisms and the impact on tamoxifen therapy. , 2007, Journal of pharmaceutical sciences.

[50]  Joshua M. Korn,et al.  Mapping and sequencing of structural variation from eight human genomes , 2008, Nature.

[51]  N. Broude,et al.  DNA amplification: current technologies and applications. , 2004 .

[52]  Larry J. Anderson,et al.  Real-Time Reverse Transcription–Polymerase Chain Reaction Assay for SARS-associated Coronavirus , 2004, Emerging infectious diseases.

[53]  F. Révillion,et al.  ERBB2 oncogene in human breast cancer and its clinical significance. , 1998, European journal of cancer.